Avidity Bio earnings missed by $0.30, revenue fell short of estimates
#Avidity Bio#RNA#Earnings Miss#Revenue Shortfall#NASDAQ#Biotechnology#Financial Health
📌 Key Takeaways
Avidity Bio missed EPS estimates by $0.30 with $-1.54 vs expected $-1.24
Revenue fell short at $860K versus $1.98M consensus forecast
Stock price has gained 150.34% over the past 12 months despite earnings miss
Company received one positive EPS revision in last 90 days
📖 Full Retelling
Avidity Bio (NASDAQ: RNA) reported first quarter earnings results on February 25, 2026, revealing an EPS of $-1.54 that missed analyst estimates by $0.30 and revenue of $860K which fell short of the $1.98M consensus forecast, as the biotechnology company faced challenges in its financial performance. Despite the disappointing earnings report, the company's stock closed at $72.80, showing resilience with a 1.53% gain over the past three months and an impressive 150.34% surge over the last twelve months, indicating investor confidence in the company's long-term prospects. Analysts had shown some optimism with one positive EPS revision in the last 90 days, though the company's financial health was rated as 'fair performance' by InvestingPro, suggesting room for improvement in meeting market expectations.
Nasdaq Stock Market (National Association of Securities Dealers Automated Quotations) is an American stock exchange, the second-largest by market cap on the list of stock exchanges, and the first fully electronic stock market. The exchange is based in Manhattan, New York City, and is among the most ...
Ribonucleic acid (RNA) is a polymeric molecule that is essential for most biological functions, either by performing the function itself (non-coding RNA) or by forming a template for the production of proteins (messenger RNA). RNA and deoxyribonucleic acid (DNA) are nucleic acids. The nucleic acids ...
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nasdaq ends more than 1% higher as Nvidia rises pre-earnings, tech extends rebound Gold prices head for fifth day of gains in six; JPMorgan sees more upside Nvidia set to report strong results and guidance, analysts say Nvidia’s results beat estimates, but Wall Street wants more cash return (South Africa Philippines Nigeria) Avidity Bio earnings missed by $0.30, revenue fell short of estimates By Investing.com Earnings Published 02/25/2026, 11:16 PM Avidity Bio earnings missed by $0.30, revenue fell short of estimates 0 RNA 0.07% Investing.com - Avidity Bio (NASDAQ: RNA ) reported first quarter EPS of $-1.54, $0.30 worse than the analyst estimate of $-1.24. Revenue for the quarter came in at $860K versus the consensus estimate of $1.98M. Avidity Bio’s stock price closed at $72.80. It is up 1.53% in the last 3 months and up 150.34% in the last 12 months. Avidity Bio saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Avidity Bio’s stock price’s past reactions to earnings here . According to InvestingPro , Avidity Bio’s Financial Health score is " fair performance ". Check out Avidity Bio’s recent earnings performance , and Avidity Bio’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
